Response assessment according to mRECIST criteria.

<p><b>Abbrevation:</b> CR: complete response; PR: partial response; SD: stable disease; PD: progression disease</p><p>Response assessment according to mRECIST criteria.</p

Inter-methods concordance between EASL and mRECIST criteria.

<p>*<b>calculated using the data reported in the paper</b></p><p>TAE: trans-arterial embolization; TACE: trans-arterial chemo-embolization; DEB TACE: drug-eluting beads trans-arterial chemoembolization.</p><p>Inter-methods concordance between EASL and mRECIST criteria.</p

Response assessment according to EASL criteria.

<p><b>Abbrevation:</b> CR: complete response; PR: partial response; SD: stable disease; PD: progression disease</p><p>Response assessment according to EASL criteria.</p

Comparison between mRECIST and EASL criteria for HCC¹⁰.

<p><b>Abbrevation:</b> HCC, hepatocellular carcinoma; mRECIST, modified Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.</p><p>Comparison between mRECIST and EASL criteria for HCC¹⁰.</p

Forest plot for HR for overall survival (responders vs non responders) according to EASL criteria.

<p>Forest plot for HR for overall survival (responders vs non responders) according to EASL criteria.</p

Timing of instrumental assessment and lesions considered.

<p>CT: computed tomography; MRI: magnetic resonance imaging; TACE: trans-arterial chemo-embolization; DEB TACE: drug-eluting beads trans-arterial chemo-embolization; RFA: radiofrequency ablation.</p><p>Timing of instrumental assessment and lesions considered.</p

Study excluded from metanalysis.

<p>Study excluded from metanalysis.</p

Flow diagram of study selection.

<p>Flow diagram of study selection.</p

Forest plot for HR for overall survival (responders vs non responders) according to mRECIST criteria.

<p>Forest plot for HR for overall survival (responders vs non responders) according to mRECIST criteria.</p